On the 9th of November, ARM (Alliance for Regenerative Medicine) together with Catapult (a British organisation for cell- and gene therapy) organised an investor day in London to present interesting and innovative companies at research’s forefront. Among those companies selected was CombiGene, which were presented by the company’s chief executive, Jan Nilsson.